DDInter1387 DDInter899
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Panobinostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nepafenac
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Posaconazole
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Panobinostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac
Panobinostat may lead to a major life threatening interaction when taken with Ivabradine
Panobinostat may lead to a major life threatening interaction when taken with Posaconazole
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Panobinostat may lead to a major life threatening interaction when taken with Flurbiprofen